KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Short-term Investments (2016 - 2025)

Historic Short-term Investments for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $42.0 million.

  • AbbVie's Short-term Investments rose 5000.0% to $42.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.0 million, marking a year-over-year increase of 5000.0%. This contributed to the annual value of $31.0 million for FY2024, which is 145000.0% up from last year.
  • According to the latest figures from Q3 2025, AbbVie's Short-term Investments is $42.0 million, which was up 5000.0% from $1.0 million recorded in Q1 2025.
  • Over the past 5 years, AbbVie's Short-term Investments peaked at $1.5 billion during Q1 2022, and registered a low of $1.0 million during Q1 2025.
  • Its 5-year average for Short-term Investments is $187.2 million, with a median of $28.0 million in 2022.
  • Its Short-term Investments has fluctuated over the past 5 years, first soared by 660000.0% in 2022, then crashed by 9951.39% in 2023.
  • AbbVie's Short-term Investments (Quarter) stood at $84.0 million in 2021, then plummeted by 66.67% to $28.0 million in 2022, then crashed by 92.86% to $2.0 million in 2023, then surged by 1450.0% to $31.0 million in 2024, then skyrocketed by 35.48% to $42.0 million in 2025.
  • Its last three reported values are $42.0 million in Q3 2025, $1.0 million for Q1 2025, and $31.0 million during Q4 2024.